Abstract
Granisetron (BRL 43694), a selective 5-HT3 receptor antagonist, was assessed as acute therapy for the first time in migraine patients. In an open pilot study 7 migraine attacks were treated in 6 patients. All but 1 patient experienced marked and rapid relief from the headache, and nausea and vomiting were rapidly resolved in the 6 cases where these symptoms accompanied the attack. No side effects were recorded. Development of granisetron for migraine was suspended during the study for extraneous reasons.
Original language | English |
---|---|
Pages (from-to) | 296-7 |
Number of pages | 2 |
Journal | Headache |
Volume | 31 |
Issue number | 5 |
Publication status | Published - May 1991 |